Navigation Links
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009

come from continuing operations in Q2 2009 includes a charge of $36.9 million following the amendment of an in-license agreement for INTUNIV. The US GAAP operating loss from continuing operations in Q2 2008 included in-process R&D charges on acquisition of METAZYM(R) from Zymenex A/S ($135.0 million) and costs associated with the cessation of commercialization of DYNEPO(TM) ($150.3 million). Excluding the above charges the fall in US GAAP operating income from continuing operations in Q2 2009 principally resulted from lower revenues following declines in branded ADDERALL XR product sales.

Net cash provided by operating activities decreased by 60% to $72.0 million for the three months to June 30, 2009 (2008: $180.4 million). The cash inflow from operating activities was lower in Q2 2009 than the same period in 2008 as lower sales receipts, higher cash tax payments and cash payments on forward exchange contracts in 2009 were only partially offset by lower operating expense payments during the quarter.

Cash, cash equivalents and restricted cash at June 30, 2009 totaled $299.1 million (December 31, 2008: $247.4 million), an increase of $51.7 million. Cash inflows from operating activities, cash received on the disposal of Shire's minority investment in Virochem Pharma Inc. and Jerini's Peptides business have been partially offset by cash outflows to acquire EQUASYM, investment in property, plant and equipment at the HGT campus in Lexington and the dividend payment.

2. Product sales

For the three months to June 30, 2009 product sales decreased by 21% to $558.4 million (2008: $705.7 million) and represented 89% of total revenues (2008: 91%). Excluding ADDERALL XR, product sales increased by 20% to $491.0 million (2008: $409.3 million).

    Product Highlights

                                                                        US
                                            
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... On August 4, 2015, the White House will ... from across the United States to talk about their experiences with innovation and present ... to be among the attendees. , One of the day’s aims is to grow ...
(Date:8/3/2015)... 3, 2015 At the 11th ... waved the shortfall of Jude Liversage,s ... for the first time.      (Photo: ... ) The Selective Dorsal Rhizotomy (SDR) ... to carry out his wish to kick a ball ...
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech ... to its comprehensive line of analytical laboratory equipment. With optimized features, such as ... provide a chemically resistant and maintenance-free solution for a broad range of vacuum ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Sterlitech Launches New Line of Vacuum Pumps 2
... A ... Biology are Natural Partners in the Fight Against Disorder. , ... (PRWEB) November 3, 2009 -- MyPhield Technology ... naturally relieves osteoarthritis without causing unwanted side-effects, is now available online at www.ReliefForLife.ca ...
... 3 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... 30, 2009. ISTA reported net revenue of $32.0 million ... increase over net revenue for the three months ended September ... months ended September 30, 2009 is $1.2 million associated with ...
... SAN MARCOS, Texas, Nov. 3 Texas State University ... agreement today that will permit University Researchers to continue ... potential and effectiveness of ALKA-V6, a compound which has ... the HIV virus in laboratory experiments. , The research ...
Cached Biology Technology:New Technology Now Available In Canada For Osteoarthritis 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 2Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 3
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... found that a class of pharmaceuticals can both prevent and ... as "TSPO ligands," are currently used for certain types of ... in young adult mice when pathology was at an early ... said lead researcher Christian Pike of the USC Davis School ...
... deadly when they metastasize and spread tumors throughout the body. ... for doctors to locate and treat the numerous tumors that ... found a way to create radioactive nanoparticles that target lymphoma ... Lewis, an associate professor of oncology in the MU College ...
... in pharmacies and health stores, phosphatidylserine is a natural ... to improve cognition and slow memory loss, it,s a ... a team headed by Prof. Gil Ast and Dr. ... Human Molecular Genetics have discovered that the same ...
Cached Biology News:Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: